Showing results (2101-2110 of 2,239) with videos related to

Sort By:
Pageof 224
Thoracic Cancer|July 8, 2020
Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patientsJing-Hua Chen, Xiang-Peng Chu, Jia-Tao Zhang, et al.
Investigational New Drugs|October 14, 2020
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancerJin-Ji Yang, Jian Fang, Yong-Qian Shu, et al.
Cell Death & Disease|August 18, 2017
Increased tumor-infiltrating CD45RA-CCR7- regulatory T-cell subset with immunosuppressive properties foster gastric cancer progressFang-Yuan Mao, Hui Kong, Yong-Liang Zhao, et al.
Clinical & Translational Immunology|June 5, 2024
Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma-like carcinomaYu-Min Zhong, Ji Chen, Jie Jiang, et al.
Advanced Materials (Deerfield Beach, Fla.)|February 20, 2020
Thermal-Disrupting Interface Mitigates Intercellular Cohesion Loss for Accurate Topical Antibacterial TherapyBenhui Hu, Christopher Berkey, Timothy Feliciano, et al.
Clinical Lung Cancer|April 15, 2018
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 TrialsYi-Long Wu, Lecia V Sequist, Eng-Huat Tan, et al.
Aging Cell|May 8, 2026
Exceptional Longevity Modifying Allele APOE2 Promotes DNA Signaling Pathways Resisting Cellular Senescence in Human NeuronsCristian Gerónimo-Olvera, Stephen M Scheeler, Carlos Galicia Aguirre, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Ebiomedicine|April 28, 2019
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trialYi-Chen Zhang, Zhi-Hong Chen, Xu-Chao Zhang, et al.
Cancer Cell|August 13, 2021
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 studyQing Zhou, Chong-Rui Xu, Ying Cheng, et al.
Pageof 224